The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2017 | What is the best sequence of treatment for NSCLC?
Johan Vansteenkiste, MD, PhD, from the University Hospitals Leuven, Leuven, Belgium, discusses recent trials in the treatment of lung cancer at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. The PACIFIC study (NCT02125461) and the FLAURA study (NCT02296125) are very promising trials in the field of lung cancer. The FLAURA trial investigated the use of TKIs in patients with EGFR mutations. The progression free survival and the hazard ratio were impressive, however, the overall survival data is still immature. The question now is what is the best sequence of treatment?
